SNPMiner Trials (Home Page)
Report for Clinical Trial NCT02455167
Developed by Shray Alag, 2020-2021.
SNP Clinical Trial Gene
1. Achieve sustained virologic response (SVR) in patients infected with HCV genotype 1,
cirrhosis, and early clinical decompensation using 12 weeks of Olysio/Sovaldi/Ribavirin
(or known as: Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin (RBV).
2. Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV)
treatment using a new test of liver function, HepQuant-SHUNT.
Name: Simeprivir (SMV)
Description: Experimental Single arm study. All participants will get the same treatment.
Type: Drug
Group Labels: 1 HCV positive group
Name: Sofosbuvir (SOF)
Description: Experimental Single arm study. All participants will get the same treatment.
Type: Drug
Group Labels: 1 HCV positive group
Name: Ribavirin (RBV)
Description: Experimental Single arm study. All participants will get the same treatment.
Type: Drug
Group Labels: 1 HCV positive group
Primary Outcomes
Measure: The sustained virologic response (SVR) in patients infected with HCV genotype 1, cirrhosis, and early clinical decompensation Time: 12 weeks
Measure: Hepatic improvement during and after Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) treatment using a new test of liver function, HepQuant-SHUNT. Time: 12 weeks
Purpose: Other
Allocation: N/A
Single Group Assignment
There is one SNP
SNPs
1 Q80K
Inclusion Criteria:
1. HCV genotype 1 infection (all subtypes and Q80K a type of mutation are allowed), and
have been approved by a third party payer for the FDA-approved combination of
sofosbuvir (SOF) plus ribavirin. --- Q80K ---